Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnesium levels linked to clotting risk in sepsis

NCT ID NCT07576621

Knowledge-focused Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 150 adults with sepsis in the ICU to see if low magnesium levels are connected to blood clotting problems. Researchers measured magnesium and clotting markers at admission and tracked outcomes like DIC and survival. The goal was to understand if magnesium could be a useful marker for clotting risk in sepsis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Apr 2025

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a Prospective observational study included adult patients diagnosed with sepsis and conducted in the intensive care units of Ain Shams University Hospitals.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 20 years at the time of Intensive Care Unit (ICU) admission. * Diagnosis of sepsis based on Sepsis-3 criteria \[confirmed or suspected infection + Sequential Organ Failure Assessment (SOFA) score ≥ 2\]. * Admission to the ICU during the study period. * Serum magnesium level measured at ICU admission. * Coagulation parameters \[e.g., platelet count, Prothrombin Time/International Normalized Ratio (PT-INR), fibrinogen, D-dimer\] within 24 hours of ICU admission. * Complete clinical and laboratory data for calculating the International Society on Thrombosis and Haemostasis (ISTH) overt Disseminated Intravascular Coagulation (DIC) score. Exclusion Criteria: * Patients with missing data on serum magnesium or coagulation markers at ICU admission. * ICU admissions due to non-infectious causes (e.g., trauma, elective surgery without infection). * Presence of pre-existing coagulopathy or hematologic malignancy affecting baseline coagulation (e.g., leukemia, hemophilia). * Known history of magnesium supplementation prior to ICU admission. * End-stage renal disease on dialysis, which may significantly alter magnesium handling. * Pregnant women, due to altered magnesium physiology. * Patients transferred from or to another hospital within 24 hours of ICU admission (incomplete follow-up).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coagulopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

blood coagulation disease familial primary hypomagnesemia infectious disease with sepsis Sepsis vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coagulopathy Hypomagnesemia Sepsis

Contacts and locations

Locations

  • Ain Shams University

    Cairo, 11591, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.